tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: EKSO BIONICS (EKSO), NovoCure (NVCR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EKSO BIONICS (EKSOResearch Report), NovoCure (NVCRResearch Report) and AC Immune SA (ACIUResearch Report) with bullish sentiments.

EKSO BIONICS (EKSO)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on EKSO BIONICS today and set a price target of $9.00. The company’s shares closed last Thursday at $1.73, close to its 52-week low of $1.54.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -2.3% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Janux Therapeutics Inc, and Corcept Therapeutics.

EKSO BIONICS has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

See Insiders’ Hot Stocks on TipRanks >>

NovoCure (NVCR)

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on NovoCure, with a price target of $115.00. The company’s shares closed last Thursday at $70.24, close to its 52-week low of $56.39.

According to TipRanks.com, Bodnar is a 1-star analyst with an average return of -2.9% and a 40.0% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as TransCode Therapeutics, Olema Pharmaceuticals, and Context Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NovoCure with a $83.33 average price target, implying a 19.2% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.

AC Immune SA (ACIU)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA today and set a price target of $16.00. The company’s shares closed last Thursday at $3.53, close to its 52-week low of $2.06.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.4% and a 35.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EKSO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More